The Cancer Gene That Breaks Every Rule Just Met Its Match
A BAP1 gene mutation guarantees cancer but makes tumors less aggressive, confounding researchers for years. Now a two-drug combination has exploited that contradiction to shrink tumors across four cancer types in mice, and both drugs already have human safety data.
Some mutations make cancer worse. Some make it better. The BAP1 gene does both, and that contradiction has frustrated researchers for years.
People who inherit a faulty BAP1 gene face a lifetime cancer risk of up to 85%, though not everyone with the mutation will develop cancer. That's the bad news. The weird part? Their tumors tend to be less aggressive than expected. But when BAP1 breaks down inside an existing cancer, the disease can become more dangerous. It's like a security guard who prevents break-ins at one house while accidentally leaving the back door open at the next one.
Scientists have now figured out how to exploit that paradox. A new preclinical study, published in Science Translational Medicine, shows that a two-drug combination shrank tumors and extended survival in mice across four different cancer types. And both drugs have already been tested in humans, which means the road to clinical trials could be shorter than usual.
The Molecular Detective Work
To understand the fix, you first need to understand what BAP1 actually does. It's a deubiquitinase, which is a fancy way of saying it's a molecular bodyguard. Its job is to protect certain proteins from being tagged for destruction by the cell's recycling machinery.
Researchers discovered that BAP1 also moonlights in DNA repair. Specifically, it plays a role in nucleotide excision repair, one of the cell's built-in systems for fixing damaged DNA. Think of it as the cell's spell-checker: it scans for errors and corrects them before they cause real problems.
When BAP1 is missing, that spell-checker gets sloppy. The research team dug deeper and identified two protein partners that BAP1 normally works with: LSD1 (a histone demethylase involved in gene regulation) and PARP1 (a well-known DNA repair enzyme). Blocking both of those partners simultaneously in BAP1-deficient cancer cells essentially overwhelms the cell's remaining repair systems, causing it to self-destruct.
It's like knocking out both backup generators in a hospital that's already lost main power. The lights go out for good.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A Familiar Toolkit, a New Strategy
The two drugs used in the combination aren't exotic newcomers. Seclidemstat, an LSD1 inhibitor originally developed by Salarius Pharmaceuticals (now part of Decoy Therapeutics), targets the first protein partner. Lynparza, the blockbuster PARP inhibitor developed by AstraZeneca and Merck, handles the second.
Lynparza is already approved for several cancer types, including ovarian and breast cancers with BRCA mutations. Using it in a new context alongside seclidemstat represents a creative bit of pharmacological recycling.
In mouse models carrying patient-derived tumors, the combination worked across a surprisingly broad range of cancers: bile duct cancer, renal cell carcinoma, mesothelioma, and uveal melanoma. That breadth matters. BAP1 mutations aren't confined to one tissue type; they pop up across the body. A single combination that addresses multiple tumor types would be a significant win.
Why "Paradox Breakers" Are Having a Moment
The BAP1 story sits within a larger trend in oncology: learning to weaponize cancer's own contradictions.
The most famous example involves BRAF inhibitors for melanoma. Drugs like vemurafenib were designed to shut down the mutant BRAF protein that drives many skin cancers. They worked brilliantly, at first. Then doctors noticed something alarming: in certain cells, the drugs activated the very pathway they were supposed to suppress. Some patients even developed new cancers as a result.
That phenomenon, called paradoxical MAPK activation, led to a generation of combination therapies (pairing BRAF inhibitors with MEK inhibitors, primarily developed to address resistance to BRAF inhibitor monotherapy, with counteracting paradoxical activation as a beneficial secondary effect) and eventually next-generation "paradox breaker" drugs like PLX8394 that avoid triggering the rebound effect altogether.
The BAP1 research follows a similar philosophical blueprint. Instead of trying to replace the missing gene, the team asked: what vulnerabilities does this loss create? Then they targeted those vulnerabilities with precision.
The Long Road From Mouse to Medicine
Before anyone gets too excited, some important caveats. This is preclinical data. Mice are not people, and the graveyard of promising mouse studies that failed in human trials is enormous. Roughly 95% of cancer drugs that work in animal models never make it to approval.
That said, the researchers have a few things working in their favor. Both drugs have existing human safety data, which eliminates one of the biggest unknowns in early drug development. The team is reportedly working with clinical and industry partners to design trials, though no timeline has been announced.
The patient population, while not massive, represents a real unmet need. BAP1-deficient mesothelioma and uveal melanoma in particular have limited treatment options. Patients with these diagnoses often cycle through therapies that weren't specifically designed for their tumor's biology.
The Bigger Picture
This study is part of a broader shift in how cancer researchers think about genetic mutations. For decades, the playbook was straightforward: find the broken protein, build a drug to block it. That approach transformed treatment for diseases like chronic myeloid leukemia and HER2-positive breast cancer.
But some mutations don't produce a hyperactive protein you can simply shut off. Some, like BAP1 loss, remove a protein entirely. You can't inhibit something that isn't there. The new strategy is subtler: map the downstream consequences of the loss and find the weak spots it creates.
It's the difference between patching a hole in a dam and rerouting the river. Both can work, but they require fundamentally different engineering.
If the BAP1 combination holds up in human trials, it won't just help patients with this specific mutation. It'll validate a way of thinking about cancer that could unlock therapies for dozens of other "loss of function" mutations that have resisted traditional drug design. The paradox, it turns out, might be the point.
4 min read
A Lung Drug Just Aced a Test It Was Never Built For
United Therapeutics' lung drug Tyvaso just posted blockbuster results in a disease it was never originally designed to treat. The IPF data could double the drug's market, and Wall Street is already doing the math.
